Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 8Terminated 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 2Plasma cell 1Gynecologic 1Gastrointestinal 1

Conditions

Melanoma 2

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × denileukin diftitox × Dermatologic × Clear all
NCT00945269 2022-11-15

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
3 enrolled
Dermatologic

Melanoma

NCT00515528 2021-01-26

Vaccination Plus Ontak in Patients With Metastatic Melanoma

University of Chicago

Phase 2 Terminated
17 enrolled 7 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡